Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Is OCAT's successful cell therapy of 31 out of 31 patients now with stable or improved vision of great importance? Got to love the benefits for AMD and SMD patients and the patents held.
The reality of the offer to purchase OCAT $8.50 is no less real than the higher worth of OCAT seen from a "true shareholders" perspective. The reason the first offer to purchase OCAT was turned down by shareholders leaves room for thought. If $8.50 is not good enough, what factors go in to finding the true value? How much could OCAT bring in with it's multi layered patented science with eyes/blood/tuffs etc. ?
What Lancet Journal documented medical solutions have you come up with to help the afflicted?
Positive developments of Dr. Lanza and team are within reach of being implemented. With that said, which opportunity would be best in the implementation?
Known along with unknown positive-OCAT outcomes are available and a valued OCAT website representing upside pathway.
Interesting OCAT quote: "Ocata's IP which has a lock on a significant portion of the regenerative med market."
RWID "relative weight of importance and duration"
A higher fairer bid and or a partner of merrit ahead is worth the thought.
Think about success and your mind moves towards it. Imagine, the five most prestigious eye institutions in the history of mankind giving the nod to OCAT SCIENCE SUCCESS. :) This is an accomplishment under the OCAT/shareholders belt.
With five of the most prestigious eye institutions in the history of mankind giving the nod to OCAT SCIENCE you cannot leave this out of the story.
While management has done whatever over the years, the OCAT/ACT science has worked tremendously to bring value to the patients and the reward to patients and shareholders is due.
There is no heaven "for me" however, prosperity for helping support OCAT Science to help patients is a good thing not a corrupt thing. If you cannot differentiate between shareholders that support the win, and management, than you have room for growth and understanding. The patients need success...get it...nothing wrong with supporting it. If you want to make justice for management "without" undermining the patients and shareholders, than i'm all ears.
There are lemons out there but not OCAT science thankfully put together by the company scientist that shareholders own shares of and support the benefits of a win/win with patients and shareholders.
Has the valued peer reviewed science that OCAT has recorded in the Lancet Journal been recieved by your mindset in the helping of patients?
Who is protecting Dr. Lanza and his science? Is it an unfairview to protect the science and keep it in this country, except to licence out when fairly paid for? If the success of the OCAT science is protected to stay here and be rewarded, who would complain then? Certainly not those that "truly" own shares or the millions of patients.
How is OCAT Dr. Lanza treated compared to Tesla?
http://listverse.com/2012/06/07/10-ways-edison-treated-tesla-like-a-jerk/
"who helps the afflicted" Lanza and supporters of the advancements of this company recorded in the Lancet Scientific Peer Reviewed Journal.
The management is another issue and should be taken separately. The real evil is to abandon and undermine the afflicted. IMO
Revealed and unrevealed data along with OCAT's patent-database set in place kind of like stacking reclaimed cargo containers and developing from dreams-to-reality. Like the guy that desired to surf-ride on the big elliott wave, OCAT's working it's way into position with institutions and determined shareholders together and Mako envelopment in a ball of fire.
rags to riches fear to courage from blind to sight who'd of thunk
http://www.huffingtonpost.com/mercedes-maidana/how-to-go-for-your-dreams_b_5739728.html
OCAT shareholders are reclaiming their future.
"Words have power if only we give them the opportunity to do so – Reclaiming Your Future"
Great OCAT Post:
"Here is why I and the majority of shareholders simply will not tender. Remember, some of us have been here for over 6 years. We can hold out a lot longer than Astellas' attrition.
1. RPE Function - The replacement of RPE cells fits elegantly into the physiology of the macula. It absorbs light and thus helps with vision, supplies nutrients to photoreceptors, digests destroyed photoreceptor outer segment membranes and allows photoreceptors to renew, secretes factors and signaling molecules to communicate with endothelial or immune system cells, and chooses to either silence or activate immune reactions. Visual function requires interactions between both RPE and photoreceptors. You can rescue photoreceptors. You can try to replace only photoreceptors, but they won't survive without the RPE.
2. RPE Transplants Prevent Progression of Dry AMD to Wet AMD - wet AMD follows the destruction of RPE and photoreceptors. Abnormal blood vessels grow when the waste products of dead photoreceptor and RPE accumulate. Called drusen, these waste deposits break down the Bruchs membrane and lead to neovascularization, or the wet form of AMD. See Regeneron.
Replacing or preventing the destruction of RPE and photoreceptor prevents the accumulation of drusen, thus preventing neovascularization.
3. Market Opportunity - The American Society of Retinal Specialists estimate 15 million Americans have AMD. No approved therapies exist for SMD or AMD.
4. Impenetrable Patent Estate - Includes the manufacturing, formulary, and therapeutic use of RPE from any pluripotent source. Similar photoreceptor progenitor patents are pending. They also have 200- some global patents pending in addition to hemangioblast-derived MSC patents.
5. Sustained Efficacy and Safety in Advanced Dry AMD Cases - Over four years of sustained visual acuity improvements or stabilization. No safety issues related to injected cells.
6. Credibility - publish data in peer reviewed journals"
Here is a why-i-wont-tender-post from yahoo.
"Why I Won't Tender for Anything Less Than 100 times Current MC
Here is why I and the majority of shareholders simply will not tender. Remember, some of us have been here for over 6 years. We can hold out a lot longer than Astellas' attrition.
1. RPE Function - The replacement of RPE cells fits elegantly into the physiology of the macula. It absorbs light and thus helps with vision, supplies nutrients to photoreceptors, digests destroyed photoreceptor outer segment membranes and allows photoreceptors to renew, secretes factors and signaling molecules to communicate with endothelial or immune system cells, and chooses to either silence or activate immune reactions. Visual function requires interactions between both RPE and photoreceptors. You can rescue photoreceptors. You can try to replace only photoreceptors, but they won't survive without the RPE.
2. RPE Transplants Prevent Progression of Dry AMD to Wet AMD - wet AMD follows the destruction of RPE and photoreceptors. Abnormal blood vessels grow when the waste products of dead photoreceptor and RPE accumulate. Called drusen, these waste deposits break down the Bruchs membrane and lead to neovascularization, or the wet form of AMD. See Regeneron.
Replacing or preventing the destruction of RPE and photoreceptor prevents the accumulation of drusen, thus preventing neovascularization.
3. Market Opportunity - The American Society of Retinal Specialists estimate 15 million Americans have AMD. No approved therapies exist for SMD or AMD.
4. Impenetrable Patent Estate - Includes the manufacturing, formulary, and therapeutic use of RPE from any pluripotent source. Similar photoreceptor progenitor patents are pending. They also have 200- some global patents pending in addition to hemangioblast-derived MSC patents.
5. Sustained Efficacy and Safety in Advanced Dry AMD Cases - Over four years of sustained visual acuity improvements or stabilization. No safety issues related to injected cells.
6. Credibility - publish data in peer reviewed journals"
Check this OCAT out.
Incredible to share this 1031 CALL options purchased TODAY vs 0 PUT options....ZERO!!!
1031 calls:0 puts
quote: "Hello????!!!!!"
Barack Attack from ICELL is a great person, i appreciate his OCAT huge-contribution to shareholders greatly.
Where is your proof that the ICELL count is not real. Those that undermine companies that are advancing in helping the afflicted are out of touch.
OCAT quote: "@Makoresearch no longer on twitter...shocker that he/they've gone into hiding."
OCAT board quote: Icell Share Count
12,437,363 Total Shares Against the Buyout 29.40%
To those that understand and hope for patients to benefit from this OCAT regenerative technology, the very best to you.
Thank you for your post Titan V.
It is my understanding that Vanguard told me differently on the 4 month topic. Another disagreement. quote from ocat poster.
"I really liked the part about Lanza having not decided yet"!
This Coming Week...
quote: "I'm wondering if maybe there will be some short covering that would boost the PPS before the tender offer closes?"
AlanC thankyou for your ability to think on your feet and express it so clear.
"Seems to me this board is split with some folks wanting the tender and others against the tender. What I don't understand is if you are for the tender why haven't you just sold already as the price has been very stable?
What is the benefit if you are for the tender to continue to hold shares and hang out here unless you are concerned your shares are worth more than is being tendered. If in fact that was the case wouldn't you be against the tender to begin with?"
OCAT shareholders have something of purpose and value.
http://msemporda.blogspot.com/2013/05/pluripotent-stem-cells-actcs-broad.html
OCAT has advanced cell technology.
"$OCAT owning greater than 50% of the O/S!"
OCAT has abilities to successfully fight eye diseases, autoimmune diseases and blood/platelet shortages. OCAT science and it's "shareholder supporters" have developed
"increased patent armament".
"This is Lanza's scientific stem cell tool kit brilliance and what makes OCATA unique in that it has ALL the necessary pieces of the puzzles and knows how to assemble them."
OCAT...a time to count no votes together.
Nice to know there is a war against eye diseases, autoimmune diseases and blood/platelet shortages. OCAT science and it's "shareholder supporters" have developed "increased patent armament".
OCAT has found a better way. That value calculated in hard to get a handle on and can be debated all day long. Not only has OCAT found a better way, it is the only way peer reviewed documented to improve vision. EOM
Not to be disagreeable however, i disagree with you profusely. The game changing OCAT science has value, tremendous value. The patients that benefited are just a start of the future. A higher bidder or a raise in offer would show solidarity about this topic.
A lot more than 200 people value OCAT science tremendously.
Japan wants OCAT because of it's accomplishments, no if's ands or butts about it. Those that do not want success do not talk about the success OCAT has. I like the fact that OCAT can have cells with out taking the cordblood of cells that should go to the newborn babies by waiting for the pulsing from the mother to the baby to be completed instead of cutting it off quickly and shiping it off to who knows where.
"Thousands of people support the company of course, because success means not only success for patients but just as importantly $$$$ in their wallets."
The Lancet Journal is a balanced report of OCAT success that many support understandably.
You seem to have never had value for the science of OCAT. Your dislike for management has been heard repeatedly year after year. However, it is very important to be aware of OCAT/ACT accomplishments and know the reason why thousands of shareholders support them. Not many can be swayed away from the very reason they invested and that reason is the benefits of the accomplishments and the future rewards of the accomplishments of OCATA/ACT. I'm not making predictions as my opinion is no better than any one else, just stating facts.
http://www.businesswire.com/news/home/20141014006693/en/ACT-Announces-Positive-Results-Clinical-Trials-Published
There is reason to support OCATA Science that was once named Advanced-Cell-Technology science.
http://www.businesswire.com/news/home/20141014006693/en/ACT-Announces-Positive-Results-Clinical-Trials-Published
1/2 Clinical Trials of RPE Cells for the Treatment of Dry Age-Related Macular Degeneration and Stargardt’s Macular Degeneration Show Positive Long Term Safety Results and Signs of Visual Improvement
The Lancet Scientific Journal OCAT/ACT study is Peer Reviewed. The information for OCAT/ACT study came from the five best eye institutions in the world for a balanced report.
What comparisons can be made if any and what is to be gained in amazing new technologies? "nikola tesla" "robert lanza"
OCAT accomplishments and future benefits and "time" is on the side of those holding "value".
Dr. Lanza and his incredible scientific team have shown the following value in documented and published papers over the past few years:
1) the ability to halt the progression of AMD and SMD in FDA/EMA approved clinical trials.
2) the ability to provide significant "human" visual acuity improvement in FDA/EMA approved clinical trials.
3) the ability to dramatically reverse MS in rats studies
4) the ability to make scalable, universal blood and platelets
5) the ability to show remission in canine's with Crohn's Disease
6) the ability to preserve kidney function and extend the lifespan of mice with lupus
If Japan is OCAT-interested, what would make anyone think that others are not as well? "Time" is always an ingredient in negotiations. The difference between the "value perspective" and "value perception" depends on the position of the viewers.